Hanmi Pharm ranked first in production of finished products among domestic pharmaceutical companies in the first half of this year with 511.8 billion won ($474 million) worth, following the first half of last year.
The production performance of domestic pharmaceutical companies’ finished drugs in the first half of this year exceeded 10 trillion won ($9.2 billion).
Despite the COVID-19 crisis, there was no disruption in the production and supply of medicines by domestic pharmaceutical companies. On the contrary, it increased 5.1 percent year-on-year.
The Ministry of Food and Drug Safety announced on Dec. 17 that production of finished drugs in Korea has steadily increased, with production in the first half of this year rising 5.1% from 9.6 trillion won in the same period last year to 10.9 trillion won.
By medicine, specialty drugs increased 6 percent to 8.5 trillion won, and general medicine increased 0.9 percent to 1.59 trillion won, indicating the outstanding growth of specialty drugs.
The top 20 manufacturers accounted for 45.3 percent (4.5 trillion won), similar to 46.1 percent (4.4 trillion won) last year.
By company, Hanmi Pharm ranked first with 511.8 billion won in the first half of 2020, up 4.2% from 491.2 billion won in the first half of 2019, maintaining the top spot following the previous year, followed by Chong Kun Dang (429.5 billion won), Daewoong Pharmaceutical (317.1 billion won), and GC Green Cross (31.3 billion won).
Kim Kang-lip, head of the Ministry of Food and Drug Safety, said, "The increase in drug production from last year despite difficult situations such as COVID-19 is due to domestic pharmaceutical companies' efforts to supply drugs. We hope that they will also work for drug safety and quality management amid heightened public interest in health."
